nodes	percent_of_prediction	percent_of_DWPC	metapath
Daunorubicin—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.367	0.569	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Mitoxantrone—lymphatic system cancer	0.278	0.431	CiPCiCtD
Daunorubicin—ABCC6—Teniposide—lymphatic system cancer	0.0522	0.177	CbGbCtD
Daunorubicin—ABCC10—Cytarabine—lymphatic system cancer	0.0405	0.137	CbGbCtD
Daunorubicin—TOP2A—Teniposide—lymphatic system cancer	0.0278	0.0942	CbGbCtD
Daunorubicin—TOP2A—Mitoxantrone—lymphatic system cancer	0.0194	0.0659	CbGbCtD
Daunorubicin—ABCC10—Vincristine—lymphatic system cancer	0.0192	0.0651	CbGbCtD
Daunorubicin—CYP1B1—Mitoxantrone—lymphatic system cancer	0.0151	0.0514	CbGbCtD
Daunorubicin—SLC22A2—Cytarabine—lymphatic system cancer	0.0142	0.0481	CbGbCtD
Daunorubicin—ABCC10—Methotrexate—lymphatic system cancer	0.0116	0.0394	CbGbCtD
Daunorubicin—ABCC1—Mitoxantrone—lymphatic system cancer	0.0108	0.0365	CbGbCtD
Daunorubicin—ABCB11—Vincristine—lymphatic system cancer	0.0104	0.0354	CbGbCtD
Daunorubicin—ABCG2—Teniposide—lymphatic system cancer	0.0103	0.035	CbGbCtD
Daunorubicin—ABCC1—Vincristine—lymphatic system cancer	0.00741	0.0251	CbGbCtD
Daunorubicin—ABCG2—Mitoxantrone—lymphatic system cancer	0.0072	0.0244	CbGbCtD
Daunorubicin—CYP1A2—Carmustine—lymphatic system cancer	0.00632	0.0214	CbGbCtD
Daunorubicin—CYP3A5—Teniposide—lymphatic system cancer	0.0057	0.0194	CbGbCtD
Daunorubicin—ABCC2—Vincristine—lymphatic system cancer	0.00548	0.0186	CbGbCtD
Daunorubicin—ABCG2—Vincristine—lymphatic system cancer	0.00496	0.0168	CbGbCtD
Daunorubicin—ABCC1—Methotrexate—lymphatic system cancer	0.00448	0.0152	CbGbCtD
Daunorubicin—ABCC2—Methotrexate—lymphatic system cancer	0.00332	0.0113	CbGbCtD
Daunorubicin—ABCG2—Methotrexate—lymphatic system cancer	0.003	0.0102	CbGbCtD
Daunorubicin—CYP3A5—Vincristine—lymphatic system cancer	0.00275	0.00932	CbGbCtD
Daunorubicin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0026	0.00881	CbGbCtD
Daunorubicin—CYP3A4—Cytarabine—lymphatic system cancer	0.00226	0.00767	CbGbCtD
Daunorubicin—CYP3A4—Teniposide—lymphatic system cancer	0.00222	0.00755	CbGbCtD
Daunorubicin—ABCB1—Vincristine—lymphatic system cancer	0.00179	0.00607	CbGbCtD
Daunorubicin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00156	0.00528	CbGbCtD
Daunorubicin—ABCB1—Methotrexate—lymphatic system cancer	0.00108	0.00367	CbGbCtD
Daunorubicin—CYP3A4—Vincristine—lymphatic system cancer	0.00107	0.00363	CbGbCtD
Daunorubicin—ABCC6—Podofilox—Teniposide—lymphatic system cancer	0.0007	0.451	CbGdCrCtD
Daunorubicin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.000166	0.107	CbGdCrCtD
Daunorubicin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.000127	0.0817	CbGdCrCtD
Daunorubicin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.00012	0.077	CbGdCrCtD
Daunorubicin—Alopecia—Bleomycin—lymphatic system cancer	8.92e-05	0.0015	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	8.91e-05	0.0015	CcSEcCtD
Daunorubicin—Stomatitis—Mitoxantrone—lymphatic system cancer	8.89e-05	0.0015	CcSEcCtD
Daunorubicin—Conjunctivitis—Mitoxantrone—lymphatic system cancer	8.87e-05	0.00149	CcSEcCtD
Daunorubicin—Urticaria—Teniposide—lymphatic system cancer	8.84e-05	0.00149	CcSEcCtD
Daunorubicin—Abdominal pain—Teniposide—lymphatic system cancer	8.8e-05	0.00148	CcSEcCtD
Daunorubicin—Body temperature increased—Teniposide—lymphatic system cancer	8.8e-05	0.00148	CcSEcCtD
Daunorubicin—Erythema—Bleomycin—lymphatic system cancer	8.79e-05	0.00148	CcSEcCtD
Daunorubicin—Hallucination—Carmustine—lymphatic system cancer	8.77e-05	0.00148	CcSEcCtD
Daunorubicin—Hyperuricaemia—Methotrexate—lymphatic system cancer	8.76e-05	0.00148	CcSEcCtD
Daunorubicin—Dyspnoea—Fludarabine—lymphatic system cancer	8.72e-05	0.00147	CcSEcCtD
Daunorubicin—Ulcer—Methotrexate—lymphatic system cancer	8.59e-05	0.00145	CcSEcCtD
Daunorubicin—Sinusitis—Mitoxantrone—lymphatic system cancer	8.56e-05	0.00144	CcSEcCtD
Daunorubicin—Decreased appetite—Fludarabine—lymphatic system cancer	8.5e-05	0.00143	CcSEcCtD
Daunorubicin—Visual impairment—Carmustine—lymphatic system cancer	8.49e-05	0.00143	CcSEcCtD
Daunorubicin—Fatigue—Fludarabine—lymphatic system cancer	8.43e-05	0.00142	CcSEcCtD
Daunorubicin—Hallucination—Vincristine—lymphatic system cancer	8.37e-05	0.00141	CcSEcCtD
Daunorubicin—Pain—Fludarabine—lymphatic system cancer	8.36e-05	0.00141	CcSEcCtD
Daunorubicin—Constipation—Fludarabine—lymphatic system cancer	8.36e-05	0.00141	CcSEcCtD
Daunorubicin—Blood uric acid increased—Methotrexate—lymphatic system cancer	8.28e-05	0.00139	CcSEcCtD
Daunorubicin—Rhinitis—Mitoxantrone—lymphatic system cancer	8.21e-05	0.00138	CcSEcCtD
Daunorubicin—Hypersensitivity—Teniposide—lymphatic system cancer	8.2e-05	0.00138	CcSEcCtD
Daunorubicin—Flushing—Carmustine—lymphatic system cancer	8.18e-05	0.00138	CcSEcCtD
Daunorubicin—Ill-defined disorder—Bleomycin—lymphatic system cancer	8.15e-05	0.00137	CcSEcCtD
Daunorubicin—Anaemia—Bleomycin—lymphatic system cancer	8.12e-05	0.00137	CcSEcCtD
Daunorubicin—Feeling abnormal—Fludarabine—lymphatic system cancer	8.06e-05	0.00136	CcSEcCtD
Daunorubicin—Asthenia—Teniposide—lymphatic system cancer	7.98e-05	0.00135	CcSEcCtD
Daunorubicin—Melaena—Methotrexate—lymphatic system cancer	7.94e-05	0.00134	CcSEcCtD
Daunorubicin—Malaise—Bleomycin—lymphatic system cancer	7.92e-05	0.00134	CcSEcCtD
Daunorubicin—Pruritus—Teniposide—lymphatic system cancer	7.87e-05	0.00133	CcSEcCtD
Daunorubicin—Arrhythmia—Carmustine—lymphatic system cancer	7.87e-05	0.00133	CcSEcCtD
Daunorubicin—Leukopenia—Bleomycin—lymphatic system cancer	7.87e-05	0.00133	CcSEcCtD
Daunorubicin—Cardiac disorder—Vincristine—lymphatic system cancer	7.81e-05	0.00132	CcSEcCtD
Daunorubicin—Alopecia—Carmustine—lymphatic system cancer	7.79e-05	0.00131	CcSEcCtD
Daunorubicin—Body temperature increased—Fludarabine—lymphatic system cancer	7.73e-05	0.0013	CcSEcCtD
Daunorubicin—Erythema—Carmustine—lymphatic system cancer	7.67e-05	0.00129	CcSEcCtD
Daunorubicin—Cough—Bleomycin—lymphatic system cancer	7.67e-05	0.00129	CcSEcCtD
Daunorubicin—Diarrhoea—Teniposide—lymphatic system cancer	7.61e-05	0.00128	CcSEcCtD
Daunorubicin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	7.55e-05	0.0486	CbGdCrCtD
Daunorubicin—Chest pain—Bleomycin—lymphatic system cancer	7.48e-05	0.00126	CcSEcCtD
Daunorubicin—Myalgia—Bleomycin—lymphatic system cancer	7.48e-05	0.00126	CcSEcCtD
Daunorubicin—Alopecia—Vincristine—lymphatic system cancer	7.43e-05	0.00125	CcSEcCtD
Daunorubicin—Back pain—Carmustine—lymphatic system cancer	7.42e-05	0.00125	CcSEcCtD
Daunorubicin—Discomfort—Bleomycin—lymphatic system cancer	7.39e-05	0.00125	CcSEcCtD
Daunorubicin—Chills—Mitoxantrone—lymphatic system cancer	7.35e-05	0.00124	CcSEcCtD
Daunorubicin—Urine output increased—Methotrexate—lymphatic system cancer	7.35e-05	0.00124	CcSEcCtD
Daunorubicin—Arrhythmia—Mitoxantrone—lymphatic system cancer	7.32e-05	0.00123	CcSEcCtD
Daunorubicin—Alopecia—Mitoxantrone—lymphatic system cancer	7.24e-05	0.00122	CcSEcCtD
Daunorubicin—Confusional state—Bleomycin—lymphatic system cancer	7.23e-05	0.00122	CcSEcCtD
Daunorubicin—Hypersensitivity—Fludarabine—lymphatic system cancer	7.21e-05	0.00121	CcSEcCtD
Daunorubicin—Tremor—Carmustine—lymphatic system cancer	7.19e-05	0.00121	CcSEcCtD
Daunorubicin—Anaphylactic shock—Bleomycin—lymphatic system cancer	7.17e-05	0.00121	CcSEcCtD
Daunorubicin—Oedema—Bleomycin—lymphatic system cancer	7.17e-05	0.00121	CcSEcCtD
Daunorubicin—Erythema—Mitoxantrone—lymphatic system cancer	7.13e-05	0.0012	CcSEcCtD
Daunorubicin—Infection—Bleomycin—lymphatic system cancer	7.12e-05	0.0012	CcSEcCtD
Daunorubicin—Anaemia—Carmustine—lymphatic system cancer	7.09e-05	0.00119	CcSEcCtD
Daunorubicin—Back pain—Vincristine—lymphatic system cancer	7.08e-05	0.00119	CcSEcCtD
Daunorubicin—Vomiting—Teniposide—lymphatic system cancer	7.08e-05	0.00119	CcSEcCtD
Daunorubicin—Agitation—Carmustine—lymphatic system cancer	7.05e-05	0.00119	CcSEcCtD
Daunorubicin—Thrombocytopenia—Bleomycin—lymphatic system cancer	7.02e-05	0.00118	CcSEcCtD
Daunorubicin—Asthenia—Fludarabine—lymphatic system cancer	7.02e-05	0.00118	CcSEcCtD
Daunorubicin—Rash—Teniposide—lymphatic system cancer	7.02e-05	0.00118	CcSEcCtD
Daunorubicin—Dermatitis—Teniposide—lymphatic system cancer	7.01e-05	0.00118	CcSEcCtD
Daunorubicin—Dysgeusia—Mitoxantrone—lymphatic system cancer	6.98e-05	0.00118	CcSEcCtD
Daunorubicin—Headache—Teniposide—lymphatic system cancer	6.97e-05	0.00117	CcSEcCtD
Daunorubicin—Pruritus—Fludarabine—lymphatic system cancer	6.92e-05	0.00117	CcSEcCtD
Daunorubicin—Lymphadenopathy—Methotrexate—lymphatic system cancer	6.91e-05	0.00116	CcSEcCtD
Daunorubicin—Back pain—Mitoxantrone—lymphatic system cancer	6.9e-05	0.00116	CcSEcCtD
Daunorubicin—Leukopenia—Carmustine—lymphatic system cancer	6.87e-05	0.00116	CcSEcCtD
Daunorubicin—Anorexia—Bleomycin—lymphatic system cancer	6.84e-05	0.00115	CcSEcCtD
Daunorubicin—Thrombophlebitis—Methotrexate—lymphatic system cancer	6.82e-05	0.00115	CcSEcCtD
Daunorubicin—Anaemia—Vincristine—lymphatic system cancer	6.77e-05	0.00114	CcSEcCtD
Daunorubicin—Agitation—Vincristine—lymphatic system cancer	6.73e-05	0.00113	CcSEcCtD
Daunorubicin—Polyuria—Methotrexate—lymphatic system cancer	6.72e-05	0.00113	CcSEcCtD
Daunorubicin—Diarrhoea—Fludarabine—lymphatic system cancer	6.69e-05	0.00113	CcSEcCtD
Daunorubicin—Convulsion—Carmustine—lymphatic system cancer	6.65e-05	0.00112	CcSEcCtD
Daunorubicin—Hypertension—Carmustine—lymphatic system cancer	6.62e-05	0.00112	CcSEcCtD
Daunorubicin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	6.62e-05	0.00111	CcSEcCtD
Daunorubicin—Nausea—Teniposide—lymphatic system cancer	6.61e-05	0.00111	CcSEcCtD
Daunorubicin—Anaemia—Mitoxantrone—lymphatic system cancer	6.59e-05	0.00111	CcSEcCtD
Daunorubicin—Leukopenia—Vincristine—lymphatic system cancer	6.55e-05	0.0011	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	6.53e-05	0.0011	CcSEcCtD
Daunorubicin—Chest pain—Carmustine—lymphatic system cancer	6.53e-05	0.0011	CcSEcCtD
Daunorubicin—Myalgia—Carmustine—lymphatic system cancer	6.53e-05	0.0011	CcSEcCtD
Daunorubicin—Anxiety—Carmustine—lymphatic system cancer	6.51e-05	0.0011	CcSEcCtD
Daunorubicin—Malaise—Mitoxantrone—lymphatic system cancer	6.43e-05	0.00108	CcSEcCtD
Daunorubicin—Dyspnoea—Bleomycin—lymphatic system cancer	6.39e-05	0.00108	CcSEcCtD
Daunorubicin—Leukopenia—Mitoxantrone—lymphatic system cancer	6.38e-05	0.00108	CcSEcCtD
Daunorubicin—Convulsion—Vincristine—lymphatic system cancer	6.34e-05	0.00107	CcSEcCtD
Daunorubicin—Hypertension—Vincristine—lymphatic system cancer	6.32e-05	0.00107	CcSEcCtD
Daunorubicin—Confusional state—Carmustine—lymphatic system cancer	6.31e-05	0.00106	CcSEcCtD
Daunorubicin—Oedema—Carmustine—lymphatic system cancer	6.26e-05	0.00105	CcSEcCtD
Daunorubicin—Decreased appetite—Bleomycin—lymphatic system cancer	6.23e-05	0.00105	CcSEcCtD
Daunorubicin—Myalgia—Vincristine—lymphatic system cancer	6.23e-05	0.00105	CcSEcCtD
Daunorubicin—Cough—Mitoxantrone—lymphatic system cancer	6.22e-05	0.00105	CcSEcCtD
Daunorubicin—Infection—Carmustine—lymphatic system cancer	6.22e-05	0.00105	CcSEcCtD
Daunorubicin—Vomiting—Fludarabine—lymphatic system cancer	6.22e-05	0.00105	CcSEcCtD
Daunorubicin—Convulsion—Mitoxantrone—lymphatic system cancer	6.18e-05	0.00104	CcSEcCtD
Daunorubicin—Rash—Fludarabine—lymphatic system cancer	6.17e-05	0.00104	CcSEcCtD
Daunorubicin—Dermatitis—Fludarabine—lymphatic system cancer	6.16e-05	0.00104	CcSEcCtD
Daunorubicin—Hypertension—Mitoxantrone—lymphatic system cancer	6.16e-05	0.00104	CcSEcCtD
Daunorubicin—Pain—Bleomycin—lymphatic system cancer	6.13e-05	0.00103	CcSEcCtD
Daunorubicin—Thrombocytopenia—Carmustine—lymphatic system cancer	6.13e-05	0.00103	CcSEcCtD
Daunorubicin—Headache—Fludarabine—lymphatic system cancer	6.13e-05	0.00103	CcSEcCtD
Daunorubicin—Tachycardia—Carmustine—lymphatic system cancer	6.11e-05	0.00103	CcSEcCtD
Daunorubicin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	6.1e-05	0.00103	CcSEcCtD
Daunorubicin—Myalgia—Mitoxantrone—lymphatic system cancer	6.07e-05	0.00102	CcSEcCtD
Daunorubicin—Chest pain—Mitoxantrone—lymphatic system cancer	6.07e-05	0.00102	CcSEcCtD
Daunorubicin—Arthralgia—Mitoxantrone—lymphatic system cancer	6.07e-05	0.00102	CcSEcCtD
Daunorubicin—Anxiety—Mitoxantrone—lymphatic system cancer	6.05e-05	0.00102	CcSEcCtD
Daunorubicin—Discomfort—Mitoxantrone—lymphatic system cancer	6e-05	0.00101	CcSEcCtD
Daunorubicin—Oedema—Vincristine—lymphatic system cancer	5.98e-05	0.00101	CcSEcCtD
Daunorubicin—Anaphylactic shock—Vincristine—lymphatic system cancer	5.98e-05	0.00101	CcSEcCtD
Daunorubicin—Anorexia—Carmustine—lymphatic system cancer	5.97e-05	0.00101	CcSEcCtD
Daunorubicin—Infection—Vincristine—lymphatic system cancer	5.94e-05	0.001	CcSEcCtD
Daunorubicin—Feeling abnormal—Bleomycin—lymphatic system cancer	5.91e-05	0.000996	CcSEcCtD
Daunorubicin—Confusional state—Mitoxantrone—lymphatic system cancer	5.87e-05	0.000989	CcSEcCtD
Daunorubicin—Thrombocytopenia—Vincristine—lymphatic system cancer	5.85e-05	0.000986	CcSEcCtD
Daunorubicin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	5.82e-05	0.00098	CcSEcCtD
Daunorubicin—Oedema—Mitoxantrone—lymphatic system cancer	5.82e-05	0.00098	CcSEcCtD
Daunorubicin—Nausea—Fludarabine—lymphatic system cancer	5.81e-05	0.000979	CcSEcCtD
Daunorubicin—Infection—Mitoxantrone—lymphatic system cancer	5.78e-05	0.000974	CcSEcCtD
Daunorubicin—Hyperhidrosis—Vincristine—lymphatic system cancer	5.78e-05	0.000973	CcSEcCtD
Daunorubicin—Shock—Mitoxantrone—lymphatic system cancer	5.73e-05	0.000965	CcSEcCtD
Daunorubicin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	5.71e-05	0.0368	CbGdCrCtD
Daunorubicin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	5.7e-05	0.000961	CcSEcCtD
Daunorubicin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	5.7e-05	0.00096	CcSEcCtD
Daunorubicin—Urticaria—Bleomycin—lymphatic system cancer	5.7e-05	0.00096	CcSEcCtD
Daunorubicin—Anorexia—Vincristine—lymphatic system cancer	5.7e-05	0.00096	CcSEcCtD
Daunorubicin—Tachycardia—Mitoxantrone—lymphatic system cancer	5.68e-05	0.000957	CcSEcCtD
Daunorubicin—Body temperature increased—Bleomycin—lymphatic system cancer	5.67e-05	0.000955	CcSEcCtD
Daunorubicin—Insomnia—Carmustine—lymphatic system cancer	5.66e-05	0.000954	CcSEcCtD
Daunorubicin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	5.63e-05	0.000948	CcSEcCtD
Daunorubicin—Mood swings—Methotrexate—lymphatic system cancer	5.59e-05	0.000942	CcSEcCtD
Daunorubicin—Dyspnoea—Carmustine—lymphatic system cancer	5.58e-05	0.00094	CcSEcCtD
Daunorubicin—Somnolence—Carmustine—lymphatic system cancer	5.57e-05	0.000938	CcSEcCtD
Daunorubicin—Anorexia—Mitoxantrone—lymphatic system cancer	5.55e-05	0.000935	CcSEcCtD
Daunorubicin—Ataxia—Methotrexate—lymphatic system cancer	5.55e-05	0.000935	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	5.44e-05	0.000917	CcSEcCtD
Daunorubicin—Decreased appetite—Carmustine—lymphatic system cancer	5.44e-05	0.000917	CcSEcCtD
Daunorubicin—Insomnia—Vincristine—lymphatic system cancer	5.4e-05	0.000911	CcSEcCtD
Daunorubicin—Pain—Carmustine—lymphatic system cancer	5.35e-05	0.000902	CcSEcCtD
Daunorubicin—Constipation—Carmustine—lymphatic system cancer	5.35e-05	0.000902	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	5.3e-05	0.000893	CcSEcCtD
Daunorubicin—Hypersensitivity—Bleomycin—lymphatic system cancer	5.28e-05	0.00089	CcSEcCtD
Daunorubicin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	5.28e-05	0.034	CbGdCrCtD
Daunorubicin—Decreased appetite—Vincristine—lymphatic system cancer	5.19e-05	0.000875	CcSEcCtD
Daunorubicin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	5.19e-05	0.0334	CbGdCrCtD
Daunorubicin—Dyspnoea—Mitoxantrone—lymphatic system cancer	5.19e-05	0.000874	CcSEcCtD
Daunorubicin—Somnolence—Mitoxantrone—lymphatic system cancer	5.17e-05	0.000872	CcSEcCtD
Daunorubicin—Feeling abnormal—Carmustine—lymphatic system cancer	5.16e-05	0.000869	CcSEcCtD
Daunorubicin—Fatigue—Vincristine—lymphatic system cancer	5.15e-05	0.000868	CcSEcCtD
Daunorubicin—Asthenia—Bleomycin—lymphatic system cancer	5.15e-05	0.000867	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Carmustine—lymphatic system cancer	5.12e-05	0.000862	CcSEcCtD
Daunorubicin—Constipation—Vincristine—lymphatic system cancer	5.11e-05	0.000861	CcSEcCtD
Daunorubicin—Pain—Vincristine—lymphatic system cancer	5.11e-05	0.000861	CcSEcCtD
Daunorubicin—Pruritus—Bleomycin—lymphatic system cancer	5.07e-05	0.000855	CcSEcCtD
Daunorubicin—Decreased appetite—Mitoxantrone—lymphatic system cancer	5.06e-05	0.000852	CcSEcCtD
Daunorubicin—Fatigue—Mitoxantrone—lymphatic system cancer	5.02e-05	0.000845	CcSEcCtD
Daunorubicin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	4.99e-05	0.0321	CbGdCrCtD
Daunorubicin—Constipation—Mitoxantrone—lymphatic system cancer	4.98e-05	0.000838	CcSEcCtD
Daunorubicin—Pain—Mitoxantrone—lymphatic system cancer	4.98e-05	0.000838	CcSEcCtD
Daunorubicin—Body temperature increased—Carmustine—lymphatic system cancer	4.95e-05	0.000834	CcSEcCtD
Daunorubicin—Abdominal pain—Carmustine—lymphatic system cancer	4.95e-05	0.000834	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Vincristine—lymphatic system cancer	4.89e-05	0.000823	CcSEcCtD
Daunorubicin—Pancytopenia—Methotrexate—lymphatic system cancer	4.84e-05	0.000816	CcSEcCtD
Daunorubicin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	4.8e-05	0.000808	CcSEcCtD
Daunorubicin—Dysuria—Methotrexate—lymphatic system cancer	4.77e-05	0.000803	CcSEcCtD
Daunorubicin—Neutropenia—Methotrexate—lymphatic system cancer	4.77e-05	0.000803	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	4.76e-05	0.000802	CcSEcCtD
Daunorubicin—Abdominal pain—Vincristine—lymphatic system cancer	4.72e-05	0.000796	CcSEcCtD
Daunorubicin—Body temperature increased—Vincristine—lymphatic system cancer	4.72e-05	0.000796	CcSEcCtD
Daunorubicin—Urticaria—Mitoxantrone—lymphatic system cancer	4.62e-05	0.000779	CcSEcCtD
Daunorubicin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	4.62e-05	0.0297	CbGdCrCtD
Daunorubicin—Hypersensitivity—Carmustine—lymphatic system cancer	4.61e-05	0.000777	CcSEcCtD
Daunorubicin—Abdominal pain—Mitoxantrone—lymphatic system cancer	4.6e-05	0.000775	CcSEcCtD
Daunorubicin—Body temperature increased—Mitoxantrone—lymphatic system cancer	4.6e-05	0.000775	CcSEcCtD
Daunorubicin—Vomiting—Bleomycin—lymphatic system cancer	4.56e-05	0.000768	CcSEcCtD
Daunorubicin—Depression—Methotrexate—lymphatic system cancer	4.53e-05	0.000764	CcSEcCtD
Daunorubicin—Rash—Bleomycin—lymphatic system cancer	4.52e-05	0.000762	CcSEcCtD
Daunorubicin—Dermatitis—Bleomycin—lymphatic system cancer	4.52e-05	0.000761	CcSEcCtD
Daunorubicin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	4.5e-05	0.0289	CbGdCrCtD
Daunorubicin—Asthenia—Carmustine—lymphatic system cancer	4.49e-05	0.000757	CcSEcCtD
Daunorubicin—Renal failure—Methotrexate—lymphatic system cancer	4.47e-05	0.000753	CcSEcCtD
Daunorubicin—Stomatitis—Methotrexate—lymphatic system cancer	4.43e-05	0.000747	CcSEcCtD
Daunorubicin—Conjunctivitis—Methotrexate—lymphatic system cancer	4.42e-05	0.000745	CcSEcCtD
Daunorubicin—Hypersensitivity—Vincristine—lymphatic system cancer	4.4e-05	0.000742	CcSEcCtD
Daunorubicin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	4.29e-05	0.000722	CcSEcCtD
Daunorubicin—Asthenia—Vincristine—lymphatic system cancer	4.29e-05	0.000722	CcSEcCtD
Daunorubicin—Diarrhoea—Carmustine—lymphatic system cancer	4.28e-05	0.000722	CcSEcCtD
Daunorubicin—Nausea—Bleomycin—lymphatic system cancer	4.26e-05	0.000718	CcSEcCtD
Daunorubicin—Asthenia—Mitoxantrone—lymphatic system cancer	4.18e-05	0.000703	CcSEcCtD
Daunorubicin—Dizziness—Carmustine—lymphatic system cancer	4.14e-05	0.000697	CcSEcCtD
Daunorubicin—Diarrhoea—Vincristine—lymphatic system cancer	4.09e-05	0.000689	CcSEcCtD
Daunorubicin—Diarrhoea—Mitoxantrone—lymphatic system cancer	3.98e-05	0.000671	CcSEcCtD
Daunorubicin—Vomiting—Carmustine—lymphatic system cancer	3.98e-05	0.000671	CcSEcCtD
Daunorubicin—Dizziness—Vincristine—lymphatic system cancer	3.95e-05	0.000666	CcSEcCtD
Daunorubicin—Rash—Carmustine—lymphatic system cancer	3.95e-05	0.000665	CcSEcCtD
Daunorubicin—Dermatitis—Carmustine—lymphatic system cancer	3.94e-05	0.000664	CcSEcCtD
Daunorubicin—Visual impairment—Methotrexate—lymphatic system cancer	3.93e-05	0.000663	CcSEcCtD
Daunorubicin—Headache—Carmustine—lymphatic system cancer	3.92e-05	0.000661	CcSEcCtD
Daunorubicin—Tinnitus—Methotrexate—lymphatic system cancer	3.81e-05	0.000641	CcSEcCtD
Daunorubicin—Vomiting—Vincristine—lymphatic system cancer	3.8e-05	0.00064	CcSEcCtD
Daunorubicin—Cardiac disorder—Methotrexate—lymphatic system cancer	3.79e-05	0.000638	CcSEcCtD
Daunorubicin—Rash—Vincristine—lymphatic system cancer	3.77e-05	0.000635	CcSEcCtD
Daunorubicin—Dermatitis—Vincristine—lymphatic system cancer	3.76e-05	0.000634	CcSEcCtD
Daunorubicin—Headache—Vincristine—lymphatic system cancer	3.74e-05	0.000631	CcSEcCtD
Daunorubicin—Nausea—Carmustine—lymphatic system cancer	3.72e-05	0.000626	CcSEcCtD
Daunorubicin—Vomiting—Mitoxantrone—lymphatic system cancer	3.7e-05	0.000623	CcSEcCtD
Daunorubicin—Rash—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000618	CcSEcCtD
Daunorubicin—Dermatitis—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000618	CcSEcCtD
Daunorubicin—Chills—Methotrexate—lymphatic system cancer	3.66e-05	0.000617	CcSEcCtD
Daunorubicin—Headache—Mitoxantrone—lymphatic system cancer	3.65e-05	0.000614	CcSEcCtD
Daunorubicin—Alopecia—Methotrexate—lymphatic system cancer	3.61e-05	0.000608	CcSEcCtD
Daunorubicin—Erythema—Methotrexate—lymphatic system cancer	3.55e-05	0.000599	CcSEcCtD
Daunorubicin—Nausea—Vincristine—lymphatic system cancer	3.55e-05	0.000598	CcSEcCtD
Daunorubicin—Dysgeusia—Methotrexate—lymphatic system cancer	3.48e-05	0.000586	CcSEcCtD
Daunorubicin—Nausea—Mitoxantrone—lymphatic system cancer	3.46e-05	0.000582	CcSEcCtD
Daunorubicin—Back pain—Methotrexate—lymphatic system cancer	3.44e-05	0.000579	CcSEcCtD
Daunorubicin—Ill-defined disorder—Methotrexate—lymphatic system cancer	3.3e-05	0.000555	CcSEcCtD
Daunorubicin—Anaemia—Methotrexate—lymphatic system cancer	3.28e-05	0.000553	CcSEcCtD
Daunorubicin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	3.22e-05	0.0207	CbGdCrCtD
Daunorubicin—Malaise—Methotrexate—lymphatic system cancer	3.2e-05	0.00054	CcSEcCtD
Daunorubicin—Leukopenia—Methotrexate—lymphatic system cancer	3.18e-05	0.000536	CcSEcCtD
Daunorubicin—Cough—Methotrexate—lymphatic system cancer	3.1e-05	0.000522	CcSEcCtD
Daunorubicin—Convulsion—Methotrexate—lymphatic system cancer	3.08e-05	0.000519	CcSEcCtD
Daunorubicin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	3.04e-05	0.0196	CbGdCrCtD
Daunorubicin—Chest pain—Methotrexate—lymphatic system cancer	3.02e-05	0.00051	CcSEcCtD
Daunorubicin—Arthralgia—Methotrexate—lymphatic system cancer	3.02e-05	0.00051	CcSEcCtD
Daunorubicin—Myalgia—Methotrexate—lymphatic system cancer	3.02e-05	0.00051	CcSEcCtD
Daunorubicin—Discomfort—Methotrexate—lymphatic system cancer	2.99e-05	0.000503	CcSEcCtD
Daunorubicin—Confusional state—Methotrexate—lymphatic system cancer	2.92e-05	0.000493	CcSEcCtD
Daunorubicin—Anaphylactic shock—Methotrexate—lymphatic system cancer	2.9e-05	0.000489	CcSEcCtD
Daunorubicin—Infection—Methotrexate—lymphatic system cancer	2.88e-05	0.000485	CcSEcCtD
Daunorubicin—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.84e-05	0.000478	CcSEcCtD
Daunorubicin—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.8e-05	0.000472	CcSEcCtD
Daunorubicin—Anorexia—Methotrexate—lymphatic system cancer	2.76e-05	0.000466	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.64e-05	0.000445	CcSEcCtD
Daunorubicin—Insomnia—Methotrexate—lymphatic system cancer	2.62e-05	0.000442	CcSEcCtD
Daunorubicin—Dyspnoea—Methotrexate—lymphatic system cancer	2.59e-05	0.000436	CcSEcCtD
Daunorubicin—Somnolence—Methotrexate—lymphatic system cancer	2.58e-05	0.000434	CcSEcCtD
Daunorubicin—Decreased appetite—Methotrexate—lymphatic system cancer	2.52e-05	0.000425	CcSEcCtD
Daunorubicin—Fatigue—Methotrexate—lymphatic system cancer	2.5e-05	0.000421	CcSEcCtD
Daunorubicin—Pain—Methotrexate—lymphatic system cancer	2.48e-05	0.000418	CcSEcCtD
Daunorubicin—Feeling abnormal—Methotrexate—lymphatic system cancer	2.39e-05	0.000403	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	2.37e-05	0.000399	CcSEcCtD
Daunorubicin—Urticaria—Methotrexate—lymphatic system cancer	2.3e-05	0.000388	CcSEcCtD
Daunorubicin—Abdominal pain—Methotrexate—lymphatic system cancer	2.29e-05	0.000386	CcSEcCtD
Daunorubicin—Body temperature increased—Methotrexate—lymphatic system cancer	2.29e-05	0.000386	CcSEcCtD
Daunorubicin—Hypersensitivity—Methotrexate—lymphatic system cancer	2.14e-05	0.00036	CcSEcCtD
Daunorubicin—Asthenia—Methotrexate—lymphatic system cancer	2.08e-05	0.00035	CcSEcCtD
Daunorubicin—Pruritus—Methotrexate—lymphatic system cancer	2.05e-05	0.000346	CcSEcCtD
Daunorubicin—Diarrhoea—Methotrexate—lymphatic system cancer	1.98e-05	0.000334	CcSEcCtD
Daunorubicin—Dizziness—Methotrexate—lymphatic system cancer	1.92e-05	0.000323	CcSEcCtD
Daunorubicin—Vomiting—Methotrexate—lymphatic system cancer	1.84e-05	0.000311	CcSEcCtD
Daunorubicin—Rash—Methotrexate—lymphatic system cancer	1.83e-05	0.000308	CcSEcCtD
Daunorubicin—Dermatitis—Methotrexate—lymphatic system cancer	1.83e-05	0.000308	CcSEcCtD
Daunorubicin—Headache—Methotrexate—lymphatic system cancer	1.82e-05	0.000306	CcSEcCtD
Daunorubicin—Nausea—Methotrexate—lymphatic system cancer	1.72e-05	0.00029	CcSEcCtD
